Relay Therapeutics to be Acquired by G42 Investments for $1.1B

Ticker: RLAY · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1812364

Relay Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRelay Therapeutics, Inc. (RLAY)
Form Type8-K
Filed DateJun 6, 2024
Risk Levelmedium
Pages5
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, merger, biotech

Related Tickers: RLAY

TL;DR

Relay Therapeutics is being bought by G42 Investments for $1.1B cash, $15/share. Deal expected Q3.

AI Summary

Relay Therapeutics, Inc. announced on June 5, 2024, that it has entered into a definitive agreement to be acquired by G42 Investments for $15.00 per share in cash. This transaction values Relay Therapeutics at approximately $1.1 billion. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition represents a significant valuation for Relay Therapeutics, potentially impacting its shareholders and the broader biotech investment landscape.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.

Key Numbers

  • $1.1B — Acquisition Value (Total enterprise value of the deal)
  • $15.00 — Per Share Price (Cash consideration for each share of Relay Therapeutics)

Key Players & Entities

  • Relay Therapeutics, Inc. (company) — Company filing the report and subject of acquisition
  • G42 Investments (company) — Acquiring company
  • $15.00 (dollar_amount) — Per share acquisition price
  • $1.1 billion (dollar_amount) — Total acquisition value
  • June 05, 2024 (date) — Date of the earliest event reported
  • third quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

What is the total value of the acquisition of Relay Therapeutics by G42 Investments?

The acquisition values Relay Therapeutics at approximately $1.1 billion.

What is the per share price offered by G42 Investments?

G42 Investments is offering $15.00 per share in cash.

When is the acquisition expected to close?

The acquisition is expected to close in the third quarter of 2024.

Who is acquiring Relay Therapeutics?

G42 Investments is acquiring Relay Therapeutics.

What is the filing date for this 8-K report?

The filing date for this 8-K report is June 6, 2024, with the earliest event reported on June 5, 2024.

Filing Stats: 1,358 words · 5 min read · ~5 pages · Grade level 15.5 · Accepted 2024-06-06 08:00:30

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RLAY Nasdaq Global Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 5, 2024, Relay Therapeutics, Inc. (the "Company") issued a press release announcing a clinical trial collaboration between the Company and Pfizer, Inc. ("Pfizer"), a copy of which is furnished herewith as Exhibit 99.1. On June 6, 2024, the Company issued a press release announcing three new programs from its existing pre-clinical pipeline, a copy of which is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company intends to host a New Program and Platform event on June 6, 2024 from 8:00 to 10:00 a.m. ET to discuss these new programs and describe how the Dynamo platform led to these discoveries. The Company has made available a slide presentation to accompany this event, a copy of which is being furnished as Exhibit 99.3 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On June 5, 2024, the Company announced a global clinical trial collaboration with Pfizer for the development of RLY-2608 in combination with fulvestrant and atirmociclib, Pfizer's investigative selective-CDK4 inhibitor, in patients with PI3K-mutated, HR+, HER2- metastatic breast cancer. On June 6, 2024, the Company announced three new programs from its existing pre-clinical pipeline, including two novel programs from its genetic disease portfolio to address clinically and commercially validated targets in vascular malformations and Fabry disease, respectively, and an NRAS-selective inhibitor. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company's strategy, business plans and focus; the progress and timing of updates on the clinical development of the programs across the Company's portfolio, including the expected therapeutic benefits of its programs, and potential efficacy and tolerability, and the timing and success of interactions with and approval of regulatory authorities; the timing of clinical data updates across the Company's pipeline, including the progress of doublet and triplet combinations for RLY-2608, the timing of clinical updates for RLY-2608, and the timing of a clinical data and regulatory update for lirafugratinib; the timing of clinical initiation of the Company's various programs, including a potential pivotal trial for RLY-2608, clinical development in vascular malformations, clinical development of the Company's non-inhibitory chaperone, and clinical development of its NRAS-selective inhibitor; the potential of the Company's product candidates to address a major unmet medical need; the cash runway projection; the competitive

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. 99.1 Press release issued by Relay Therapeutics, Inc. on June 5, 2024, furnished herewith. 99.2 Press release issued by Relay Therapeutics, Inc. on June 6, 2024, furnished herewith. 99.3 New Program and Platform event presentation, dated June 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RELAY THERAPEUTICS, INC. Date: June 6, 2024 By: /s/ Brian Adams Brian Adams Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.